Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

July 16, 2007 at 10:57 AM

Debate on biotech drug generics lies ahead

The House of Representatives voted last week to strengthen the U.S. Food and Drug Administration’s rule over drug companies, but the fate of biotech drug generics is yet to be written, according to this Wall Street Journal story.

The House bill must be reconciled with a measure recently passed by the Senate, opening the way to follow-on biologics, as identical copies of biotech drugs are known. Biotech companies — including many local firms — dread their coming.

The current Senate bill would allow the FDA to waive clinical trials for generic versions of already approved drugs, something that could eliminate most of the incentive to develop costly therapies and pose a safety risk, opponents say. Supporters say generics could lower health care costs and increase access to life-saving medicines.

“A compromise version of the two measures is expected to be completed in the next few months,” the Journal story says.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►